Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone

Haematologica

Volumn 91, Issue 7, 2006, Pages 929-934

  Jagannath, Sundar ^a   Richardson, Paul G ^b   Barlogie, Bart ^c   Berenson, James R ^d   Singhal, Seema ^e   Irwin, David ^f   Srkalovic, Gordan ^g   Schenkein, David P ^h   Esseltine, Dixie L ^h   Anderson, Kenneth C ^b  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^f Alta Bates Cancer Center   (United States)

^g Department of Medical Oncology and Hematology   (United States)

^h MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Dexamethasone; Multiple myeloma; Phase 2

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPONATREMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; PERIPHERAL EDEMA; RECURRENT DISEASE; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 33745801771     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview? of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998;16:3832-42.
2. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc 2002;77:813-22.
3. Segeren CM, Sonneveld P, van der HB, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144-51.
4. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
5. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
6. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003;121:768-71.
7. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826-31.
8. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
9. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90.
10. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
11. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow? stromal cells involves activation of NF-κB. Blood 1996;87:1104-12.
12. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κ B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
13. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
14. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
15. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
16. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
17. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
18. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-23.
20. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/ctcv2nom-4-30-99- final3.pdf.
21. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
22. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai Y-T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
23. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-4.
24. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med 2000; 342:1554-9.
25. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-14.
26. Huang SY, Tang JL, Yao M, Ko BS, Hong RL, Tsai W, et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol 2003;82:558-64.
27. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001;344:1951-52.